Table 5. Recurrence free survival, of patients by the type of surgery, within BRCA1/2 mutation carriers and noncarriers (N=469).
| BRCA1/2 mutation status | Type of surgery | No. | No. events | Person-years | Events/1,0000 person-years | 5-y cum survival | CI |
|---|---|---|---|---|---|---|---|
| BRCA1/2 | |||||||
| Mastectomy (combined) | 132 | 5 | 7,174 | 7 | 0.93 | 0.85–1.00 | |
| Breast-conserving therapy | 44 | 4 | 2,529 | 16 | 0.95 | 0.89–1.00 | |
| Noncarriers | |||||||
| Mastectomy (combined) | 213 | 17 | 6,540 | 26 | 0.83 | 0.71–0.95 | |
| Breast-conserving therapy | 80 | 10 | 2,288 | 44 | 0.67 | 0.42–0.89 |
5-y cum survival, 5-year cumulative recurrence-free survival; Breast-conserving therapy, combined, without radiotherapy or followed by radiotherapy. CI, 95% confidence interval; Events/10,000 person-years, number of events per 10,000 person-years; No. events, number of events during follow-up; No., number of patients at the start of follow-up; Person-years, the sum of person-years of follow-up.